Page 4 - CiTRUS Demo

We are viewed as thought partners for solving client problems
UNCOVER * HYPOTHESIZE * VALIDATE * SYNTHESIZE * PLAN
What is the environment What drives differentiation we are entering? among stakeholders?
Value assessment
How do we maximize the global asset value?
Decision drivers
Market dynamics and buying infrastructure
• Unmet medical need
• Disease burden, epidemiology
• Patient journey and pain points with clinicians and reimbursement bodies
• Clinician prescribing levers and therapeutic treatment algorithm
• Key competitors
• Payer management trends
• Settings of care, channels, and funding flows
• Meaningful clinical benefits to patients, clinicians, and payers
• Economic and QoL benefits
• Robustness of evidence, trial rigor
• Optimal trial designs— need for H2H, choice of comparator, trial duration, long term follow up, endpoints, indications, populations
• Optimal positions in the treatment algorithm, labeling, patient subpopulations
• Weigh trade-offs between clinical positioning, reimbursement, access in order to optimize market entry
• Balance the value of subsequent but uncertain lifecycle indications
• Consider cross-market, cross- indication risks over the lifecycle
• Rigorous global asset planning: seamlessly integrating expertise of marketing-medical-market access (3M) into cohesive global plan
4